UNSPSC 51152043: Promoxolane

This classification denotes a muscle relaxant with the molecular formula C10H20O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JHI9RRY52E, chemically known as 2,2-diisopropyl-4-methanol-1,3-dioxolane but generally known as promoxolane, which bears US NIH Compound Identifier 10105. European Medicines Agency schedules Promoxolane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10091MIG.

UNSPSC 51152043 Promoxolane is a Commodity code that encompasses naloxone and drug deactivation systems being procured by state and local public health authorities to support community health and opioid emergency-response initiatives. State and local governments are acquiring naloxone units and associated safe drug deactivation equipment through competitive bidding processes, with delivery and inventory-management components built into vendor scope. Issuing bodies include county health departments and state health and human services agencies, which are the primary buyers under this code. The procurement includes standard compliance requirements — E-Verify, drug-free workplace certification, and various insurance coverages — and may carry federal funding implications through FEMA or other health-related grant programs that introduce additional environmental and regulatory adherence obligations.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's Community Health Building, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs that would include pharmaceutical fulfillment outside traditional pharmacy benefit manager channels, signaling broader state-level interest in supply-chain modernization for pharmaceutical products. The Seminole County procurement specifies a two-year initial term with one-year renewal option and a three-month probationary termination window, while the Texas RFI remains exploratory and does not yet carry formal evaluation criteria or budget commitments.